End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

Background: Previous analyses from a randomised trial in women aged 24–45 years have shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external genital lesions (EGLs) related to HPV 6/11/16/18. I...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2011-06, Vol.105 (1), p.28-37
Hauptverfasser:	Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
Format:	Artikel
Sprache:	eng
Schlagworte:	631/326/596/2560 631/61/51/1868 631/92/436/108 692/699/67/1517/1371 Adult Age Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cervical Intraepithelial Neoplasia - immunology Cervical Intraepithelial Neoplasia - prevention & control Cervical Intraepithelial Neoplasia - virology Cervix Clinical Study Clinical Trials as Topic Combined vaccines Data processing Double-Blind Method Drug Resistance Epidemiology Female Follow-Up Studies Human papillomavirus Humans Immunogenicity International Agencies Medical sciences Middle Aged Molecular Medicine Multicenter Studies as Topic Neoplasia Oncology Ovarian Neoplasms - immunology Ovarian Neoplasms - prevention & control Ovarian Neoplasms - virology Papillomaviridae - immunology Papillomavirus Infections - immunology Papillomavirus Infections - prevention & control Papillomavirus Infections - virology Papillomavirus Vaccines - immunology Papillomavirus Vaccines - therapeutic use Persistent infection Randomized Controlled Trials as Topic Sampling Treatment Outcome Tumors Vaccination Vaccines Vaccines, Synthetic - immunology Vaccines, Synthetic - therapeutic use Warts Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!